NEW YORK (GenomeWeb News) —  Epigenomics yesterday said it has transferred its PCR-based prostate cancer prognostic test to Affymetrix’ GeneChip platform.
The company said a concordance study showed a 98-percent agreement between the two platforms.  
Epigenomics said the development of its test is “on track” and expecting to begin clinical trials in the US and Europe some time in 2007.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Sponsored by

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Sponsored by

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.